<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04023864</url>
  </required_header>
  <id_info>
    <org_study_id>GCWB-BF-PG</org_study_id>
    <nct_id>NCT04023864</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Platycodon Grandiflorus Extract(GCWB107) on Decrease of Body Fat</brief_title>
  <official_title>A 12-week, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Platycodon Grandiflorus Extract(GCWB107) on Decrease of Body Fat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chonbuk National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was conducted to investigate the effects of daily supplementation of Platycodon
      grandiflorus extract(GCWB107) on decrease of body fat.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was a 12-week, randomized, double-blind, placebo-controlled human trial. 80
      subjects were randomly divided into Platycodon grandiflorus extract(GCWB107) group and a
      placebo group. It is to evaluate the changes in the displayed evaluation items when taking
      Platycodon grandiflorus extract(GCWB107) extract once a day, in comparison with taking a
      placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of body fat mass</measure>
    <time_frame>0 week and 12 week</time_frame>
    <description>Body fat mass was measured in study baseline and 12 week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of percent body fat</measure>
    <time_frame>0 week and 12 week</time_frame>
    <description>Measurement is made using dual-energy X-ray absorptiometry (DEXA / Hologic Discovery, USA). Left-arm, right arm, left leg, right leg, trunk, total will be reported percent body fat in %.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of fat free mass</measure>
    <time_frame>0 week and 12 week</time_frame>
    <description>Measurement is made using dual-energy X-ray absorptiometry (DEXA / Hologic Discovery, USA). Left-arm, right arm, left leg, right leg, trunk, total will be reported fat free mass in g.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Anthropometric indicators</measure>
    <time_frame>Screening, 0 week, and 12 week</time_frame>
    <description>Anthropometric indicators(i.e., weight, body mass index, waist circumference, hip circumference, waist-hip ratio) were measured in study screening, 0 weeks, and 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of indicator of lipid metabolism</measure>
    <time_frame>0 week and 12 week</time_frame>
    <description>Indicators of lipid metabolism(i.e., Total cholesterol, Triglyceride, LDL-cholesterol, HDL-cholesterol) were measured in the study for 0 weeks and 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Obesity-related hormone index</measure>
    <time_frame>0 week and 12 week</time_frame>
    <description>Obesity-related hormone indexes(i.e., Adiponectin, Leptin)were measured in the study for 0 weeks and 12 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Body Fat</condition>
  <arm_group>
    <arm_group_label>Platycodon Grandiflorus Extract(GCWB107) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once-daily, once a tablet, after meals (900 mg/day, 571 mg/day as a Platycodon Grandiflorus Extract(GCWB107))</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once-daily, once a tablet, after meals (900 mg/day, 0 mg/day as a Platycodon Grandiflorus Extract(GCWB107))</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Platycodon Grandiflorus Extract(GCWB107)</intervention_name>
    <description>Once-daily, once a tablet, after meals, for 12 week</description>
    <arm_group_label>Platycodon Grandiflorus Extract(GCWB107) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 12 week</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged between 19 and 65 years at the screening

          -  Participants who were BMI 25~29.9 kg/m^2

          -  Participants who have fully understood the information provided about the study
             voluntarily decided to participate and agreed to comply with precautions

        Exclusion Criteria:

          -  Participants who decrease 10% more of weight within 3 months period to the screening
             examination

          -  Participants taking for products affecting body weight within 4 weeks before the
             screening examination(i.e., Improvement of body fat Healthy functional food,
             contraceptive, steroid drug treatment, female hormone drug treatment) (However,
             participation is possible after a 4-week withdrawal period prior to the first intake
             day)

          -  Participants who drink more than 14 units/week of alcohol intake

          -  Patients with a clinically significant acute or chronic cardiovascular system,
             endocrine system, immune system, respiratory system, liver biliary system, kidney and
             urinary system, neuropsychiatry system, musculoskeletal system, inflammatory and
             hematologic

          -  Patients with diabetics who are taking oral hypoglycemic agents and insulin (at the
             screening)

          -  Participants with a past history of gastrointestinal diseases (e.g., Crohn's disease)
             or gastrointestinal surgery (but, excluding simple cecal surgery and hernia surgery)
             that can affect the absorption of products of the human trial

          -  Participants who have a history of clinically significant hypersensitivity to balloon
             flower and saponin components

          -  Participants receiving antipsychotic medication within 2 months prior to the screening
             examination

          -  Participants who were doubtful about drug abuse

          -  Participants who have participated in other clinical trials within 3 months prior to
             the screening examination

          -  Participants who have SBP≥180 mmHg and DBP≥110 mmHg

          -  Menopause women

          -  Participants who show the following relevant results in a Laboratory test

               -  Aspartate Transaminase(AST), Alanine Transaminase(ALT) &gt; Reference range 3 times
                  upper limit

               -  Serum Creatinine &gt; 2.0 mg/dl

          -  Women who are pregnant or breastfeeding

          -  Women who may become pregnant and have not used appropriate contraceptives

          -  Participants who the principal investigator judged inappropriate for the participant
             in this study because of a laboratory test result, etc
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Soo Wan Chae, Ph.D., M.D.</last_name>
    <phone>82-63-259-3040</phone>
    <email>soowan@jbnu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Center for Functional Foods Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo-Wan Chae, MD., PhD</last_name>
      <phone>82-63-259-3040</phone>
      <email>swchae@jbctc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>July 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2019</study_first_posted>
  <last_update_submitted>November 28, 2019</last_update_submitted>
  <last_update_submitted_qc>November 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonbuk National University Hospital</investigator_affiliation>
    <investigator_full_name>Soo-Wan Chae</investigator_full_name>
    <investigator_title>Principal Investigator, Clinical Trial Center for Functional Foods</investigator_title>
  </responsible_party>
  <keyword>Platycodon Grandiflorus Extract</keyword>
  <keyword>Body Fat</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

